Correction (JACC: Heart Failure (2019) 7(12) (1012–1021), (S2213177919307358), (10.1016/j.jchf.2019.08.017));MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT

JACC: Heart Failure

Volumn 7, Issue 12, 2019, Pages 1012-1021

  Ferreira, João Pedro ^a   Rossello, Xavier ^b,c   Eschalier, Romain ^d   McMurray, John J V ^e   Pocock, Stuart ^f   Girerd, Nicolas ^a   Rossignol, Patrick ^a   Pitt, Bertram ^g   Zannad, Faiez ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c CIBER de enfermedades Cardio Vasculares ^*  (Spain)

^d SERVICE DE RHUMATOLOGIE   (France)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

elderly; mineralocorticoid receptor antagonists; treatment effects

Indexed keywords

MINERALOCORTICOID ANTAGONIST; EPLERENONE; SPIRONOLACTONE;

AGE; ALL CAUSE MORTALITY; ARTICLE; DEATH; DIABETES MELLITUS; ESTIMATED GLOMERULAR FILTRATION RATE; HEART DEATH; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART STROKE VOLUME; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; EPLERENONE; FEMALE; HEART FAILURE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; STROKE VOLUME;

EID: 85074995067     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2020.03.001     Document Type: Erratum

References (26)

1. Bleumink, G.S., Knetsch, A.M., Sturkenboom, M.C., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam Study. Eur Heart J 25 (2004), 1614–1619.
2. Zannad, F., Rising incidence of heart failure demands action. Lancet 391 (2018), 518–519.
3. Conrad, N., Judge, A., Tran, J., et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391 (2018), 572–580.
4. Dharmarajan, K., Rich, M.W., Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin 13 (2017), 417–426.
5. Mogensen, U.M., Ersboll, M., Andersen, M., et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 13 (2011), 1216–1223.
6. Lazzarini, V., Mentz, R.J., Fiuzat, M., Metra, M., O'Connor, C.M., Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail 15 (2013), 717–723.
7. Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
8. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341 (1999), 709–717.
9. Zannad, F., McMurray, J.J., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (2011), 11–21.
10. Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
11. Ferreira, J.P., Girerd, N., Rossignol, P., Zannad, F., Geographic differences in heart failure trials. Eur J Heart Fail Eur J Heart Fail 17 (2015), 893–905.
12. de Denus, S., O'Meara, E., Desai, A.S., et al. Spironolactone metabolites in TOPCAT: new insights into regional variation. N Engl J Med 376 (2017), 1690–1692.
13. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 68 (2016), 1476–1488.
14. Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
15. Pitt, B., Pedro Ferreira, J., Zannad, F., Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 3 (2017), 48–57.
16. da Costa, B.R., Juni, P., Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J 35 (2014), 3336–3345.
17. Riley, R.D., Lambert, P.C., Abo-Zaid, G., Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ, 340, 2010, c221.
18. Levy, D., Kenchaiah, S., Larson, M.G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 (2002), 1397–1402.
19. Vaduganathan, M., Patel, R.B., Michel, A., et al. Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol 69 (2017), 556–569.
20. Ferreira, J.P., Mentz, R.J., Pizard, A., Pitt, B., Zannad, F., Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. Eur J Heart Fail 19 (2017), 974–986.
21. Eschalier, R., McMurray, J.J., Swedberg, K., et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 62 (2013), 1585–1593.
22. Rossignol, P., Ferreira, J.P., Balancing benefits and risks of spironolactone in HFpEF and chronic kidney disease patients: mind the gap of biological monitoring!. J Am Coll Cardiol HF 7 (2019), 33–35.
23. Ferreira, J.P., Abreu, P., McMurray, J.J.V., et al. Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. Eur J Heart Fail 21 (2019), 345–351.
24. Ferreira, J.P., Barros, A., Pitt, B., et al. Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial. Clin Res Cardiol 107 (2018), 1192–1195.
25. Ferreira, J.P., Rossignol, P., Pizard, A., et al. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart 105 (2019), 307–314.
26. Iqbal, J., Parviz, Y., Pitt, B., Newell-Price, J., Al-Mohammad, A., Zannad, F., Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail 16 (2014), 143–150.